|
受注:045-509-1970 |
技術サポート:tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
|
Synonyms | APTA 2217, B9302-107, BY 217, BYK 20869 | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
|||
| 化学式 | C17H14Cl2F2N2O3 |
||||||
| 分子量 | 403.21 | CAS No. | 162401-32-3 | ||||
| Solubility (25°C)* | 体外 | DMSO | 81 mg/mL (200.88 mM) | ||||
| Ethanol | 21 mg/mL (52.08 mM) | ||||||
| Water | Insoluble | ||||||
| 体内 (毎回新しく調製した物を用意してください) |
|
||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||||||
| 製品説明 | Roflumilast is a selective inhibitor of PDE4 with IC50 of 0.2-4.3 nM in a cell-free assay. |
|---|---|
| in vitro | Roflumilast displays anti-inflammatory and immunomodulatory in vitro. This compound inhibits LTB4 synthesis in human neutrophil with IC50 of 2 nM. It inhibits fMLP-stimulated ROS formation as luminol-enhanced CL in human neutrophils or eosinophils with IC35 of 4 nM, and 7 nM, repectively. The chemical inhibits LPS-stimulated TNF-α synthesis in monocytes with IC40 of 21 nM. It inhibits TNF-α synthesis in monocyte-derived dendritic cells with IC20 of 5 nM. This compound inhibits anti-CD3 and anti-CD28 antibody-stimulated proliferation of CD4+ T cells with IC30 of 7 nM. It inhibits anti-CD3 and anti-CD28 antibody-stimulated synthesis of IL-2, IL-4, IL-5, and IFN-v in CD4+ T cells with IC20 of 1 nM, IC30 of 7 nM, IC25 of 13 nM, and IC35 of 8 nM, respectively. [2] |
| in vivo | Roflumilast is activity against pulmonary inflammatory response related to COPD in animal model. This compound (5 mg/kg/day) induces reduction of neutrophils, macrophages, DC, B-cells, CD4+ T cells, CD8+ T cells in the lung of mice exposed to tobacco smoke for 7 month by 78%, 82%, 48%, 100%, 98%, and 88%, respectively. [3] It is an efficient inhibitor of lung fibrotic remodeling. This chemical dose-dependently diminishes total lung hydroxyproline after bleomycin, attaining about 47% inhibition at 5 mg/kg/day, paralleled by a reduction in lung αI(I) collagen transcripts and fibrotic lesions. It reduces oxidative stress in vivo. This compound (5 mg/kg/day) moderately reduces an increase in BAL fluid lipid hydroperoxides measured at day 14 after intratracheal bleomycin administration in mice. [4] |
| キナーゼアッセイ | PDE activity assay | |
|---|---|---|
| The assay mixture contains 50 mM Tris (pH 7.4), 5 mM MgCl2, 0.5 μM cAMP or cGMP, and [3H]cAMP or [3H]cGMP (about 30,000 cpm/assay), the indicated concentration of the inhibitor and an aliquot of the enzyme solution at a final assay volume of 200 μL.Stock solutions of the compounds are diluted 1:100 (v/v) in the Tris buffer; appropriate dilutions are prepared in 1% (v/v) DMSO/Tris buffer, which are diluted 1:2 (v/v) in the assays to obtain the desired final concentrations of the inhibitors at a DMSO concentration of 0.5% (v/v). DMSO itself affects none of the PDE activity.After preincubation for 5 min at 37 ℃, the reaction is started by the addition of substrate (cAMP or cGMP) and the assays are incubated for further 15 min at 37 ℃. Then 50 μL of 0.2 N HCl is added to stop the reaction and the assays are left on ice for about 10 min. Following incubation with 25 μg of 5’-nucleotidase for 10 min at 37 ℃, the assays are loaded on QAE Sephadex A-25 (1 mL of bed volume in Poly-Prep chromatography column). The columns are eluted with 2 mL of 30 mM ammonium formate (pH 6.0) and the eluate is counted for radioactivity. Results are corrected for blank values (measured in the presence of denatured protein) that are below 5% of total radioactivity. The amount of cyclic nucleotides hydrolyzed does not exceed 30% of the original substrate concentration. | ||
|

Data from [J Mass Spectrom, 2012, 47, 1612-1619 ]
| PDE4D inhibition ameliorates cardiac hypertrophy and heart failure by activating mitophagy [ Redox Biol, 2025, 81:103563] | PubMed: 40015131 |
| Roflumilast Attenuates Microglial Senescence and Retinal Inflammatory Neurodegeneration Post Retinal Ischemia Reperfusion Injury Through Inhibiting NLRP3 Inflammasome [ Invest Ophthalmol Vis Sci, 2024, 65(12):38] | PubMed: 39446353 |
| Functional rescue of CFTR in rectal organoids from patients carrying R334W variant by CFTR modulators and PDE4 inhibitor Roflumilast [ Respir Investig, 2024, 62(3):455-461] | PubMed: 38547757 |
| PDE4D binds and interacts with YAP to cooperatively promote HCC progression [ Cancer Lett, 2022, 541:215749] | PubMed: 35597479 |
| Long-Acting β2 Adrenergic Receptor Agonist Ameliorates Imiquimod-Induced Psoriasis-Like Skin Lesion by Regulating Keratinocyte Proliferation and Apoptosis [ Front Pharmacol, 2022, 13:865715] | PubMed: 35795567 |
| Estimulantes y Activadores de la Guanilato Ciclasa en el Tratamiento del Asma y la Enfermedad Pulmonar Obstructiva Crónica [ University of Valencia, 2022, ] | PubMed: None |
| Phosphodiesterase 4A confers resistance to PGE2-mediated suppression in CD25+ /CD54+ NK cells [ EMBO Rep, 2021, e51329] | PubMed: 33480074 |
| Roflumilast prevents ischemic stroke-induced neuronal damage by restricting GSK3β-mediated oxidative stress and IRE1α/TRAF2/JNK pathway [ Free Radic Biol Med, 2021, 163:281-296] | PubMed: 33359910 |
| Actionable Cytopathogenic Host Responses of Human Alveolar Type 2 Cells to SARS-CoV-2 [ Mol Cell, 2020, 80(6):1104-1122.e9] | PubMed: 33259812 |
| Hyperinsulinemia promotes heterologous desensitization of β2 adrenergic receptor in airway smooth muscle in obesity. [ FASEB J, 2020, 10.1096/fj.201800688RR] | PubMed: 31960515 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。